LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply. Birgitta, an experienced CMC project manager with several leading positions at development and commercial stage pharmaceutical companies, will join Spago Nanomedical on June 1 and serve as a member of the management team.
"I am very pleased to welcome Birgitta to Spago Nanomedical. As Head of CMC & Supply, Birgitta's broad managerial and technical experience in regulatory CMC and pharmaceutical development, both clinical and non-clinical, will be of great importance in advancing our pipeline. Her experience from managing contract manufacturers, ensuring all operations meet delivery and quality standards, will also play an important role as we take our lead program Tumorad into the next phase," said Mats Hansen, CEO of Spago Nanomedical.
Birgitta joins from the Danish commercial stage pharmaceutical company MC2 Therapeutics where she was CMC Project Manager since 2021. Previous positions include e.g. Head of Development at Sever Pharma Solutions AB and Bioglan AB, respectively. Birgitta holds a Ph. D. in physical chemistry and a M. Sc. in chemistry from Lund University.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, [email protected]
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.
Attachments
Spago Nanomedical strengthens management with Head of CMC & Supply
SOURCE: Spago Nanomedical